Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
MoAbs targeting the tumourigenic pathways such as
2021-06-11

MoAbs targeting the tumourigenic pathways, such as IGF-1R may theoretically have a dual working mechanism. On the one hand they block pathways having an anti-tumour working mechanism, and on the other hand they may also stimulate an immunological response inducing a reaction of the patients own immu
-
Although several genomic technologies including the
2021-06-11

Although several genomic technologies, including the generation of ERRγ-specific knockout mice, have revealed that ERRγ plays a pivotal role in cellular bioenergetics [1], its involvement in other metabolic pathways has been appreciated only recently. Therefore, we highlight recent findings on the r
-
br Introduction Our understanding of how ligands interact wi
2021-06-11

Introduction Our understanding of how ligands interact with G protein coupled receptors is evolving, particularly the recognition that some have the ability to preferentially activate a subset of intracellular signalling cascades – so called pathway biased ligands [1]. Additionally, it is now acc
-
br Acknowledgements We would like to thank Dr
2021-06-11

Acknowledgements We would like to thank Dr Ron Mason (NIEHS, Research Triangle Park, NC) for helpful discussion regarding the analysis of CCl4 metabolism, to Dr Karla Thrall and Dr Rick Corley (Battelle) for helpful discussions regarding study design and data interpretation, and to Jim Merdink an
-
In the phase I AURA trial patients with EGFR
2021-06-11

In the phase I AURA trial, patients with EGFR activating mutations and centrally confirmed tumor and/or plasma genotyping (BEAMing) T790M result were enrolled. Among 216 patients with both plasma and tissue genotyping results, the concordance rate was 82% for phalloidin sale 19 deletions, 86% for L
-
br Introduction The Epstein Barr virus induced
2021-06-11

Introduction The Epstein–Barr virus induced gene 2 (EBI2 also known as GPR183) is a G protein-coupled seven-transmembrane (7TM) receptor that is predominantly expressed in B and T cells [1,2]. It regulates the trafficking of Argatroban within lymphoid tissues and is highly important for the gene
-
br A brief history of RBR E s
2021-06-11

A brief history of RBR E3s RBR E3s were originally defined based on sequence alignments that predicted a tripartite motif of three zinc (Zn)-binding domains: two RING domains (RING1 and RING2) connected via an in-between-RING (IBR) domain [28], [29]. The prediction together with initial observati
-
Tailoring pharmacological treatment to the
2021-06-11

Tailoring pharmacological treatment to the genetic background of a person can enhance therapeutic response (), increase compliance (), and decrease drug toxicity (, , ). Because cocaine addiction has a strong genetic basis, with the vulnerability to develop an addiction estimated to be as high as 72
-
br Development of the double strand break repair model
2021-06-10

Development of the double strand break repair model for meiotic recombination Meiotic recombination was first described by Frans Alfons Janssens using AZ505 in the salamander Batracoseps attenuatus in 1909 [21] and then further elaborated at the genetic level in Drosophila by Thomas H. Morgan [2
-
Since anti MMP Therapy anti iNOS therapy
2021-06-10

Since, anti-MMP Therapy [9], anti-iNOS therapy [10], TNF-α and IL-1β inhibitor (Diacerhein) [11] etc. are some of the disease modifying anti-osteoarthritis drugs have been used. But their action based on the evidence from the clinical trial and scientific literature suggesting the therapeutic effica
-
MDL 12330A hydrochloride br Materials and methods br Results
2021-06-10

Materials and methods Results Discussion TP has aroused extensive explorations because of its potent anti-inflammatory, immune-suppressive and antitumor activities. Notwithstanding these, TP has yet to enter Phase II clinical trials owing to its severe toxicity (Zhou et al., 2012). TP could
-
With a favorable spectrum of CRTh dependent in vitro and
2021-06-10

With a favorable spectrum of CRTh2 dependent in vitro and in vivo efficacy demonstrated, the off-target activity of compound 18 was investigated, first against a panel of prostanoid receptors and related eicosanoid targets (Table 8), where no significant activities at 10μM concentration were found i
-
br Results On the th day the horizontal Fig
2021-06-10

Results On the 8th day, the horizontal (Fig. 1) and vertical locomotor activity (Fig. 2) and the dorsal (Fig. 3) and Agarose GPG/ME australia striatal dopamine release (Fig. 4) increased significantly in nicotine-treated rats, compared with the saline-treated rats. Tukey post-hoc test revealed t
-
Sterol regulatory element binding proteins SREBPs regulate
2021-06-10

Sterol regulatory element binding proteins (SREBPs) regulate transcription of genes involved in fatty VX-661 synthesis synthesis [38] (fatty acid synthase, and acetyl-CoA carboxylase) as well as triglyceride synthesis [39]. SREBP-1 protein levels are reduced in 3T3-F442A adipocytes [40] and increas
-
UCB 35625 Depending on the needs of the product to
2021-06-10

Depending on the needs of the product to be preserved, there are several levels of barrier packaging. Usually they are classified into low and high barriers. High barriers have a low oxygen transmittal rate, low moisture vapor transmission rate, and a high tensile strength, or puncture resistance. W
15830 records 612/1056 page Previous Next First page 上5页 611612613614615 下5页 Last page